Literature DB >> 23021288

Epilepsy in poor regions of the world.

Charles R Newton1, Hector H Garcia.   

Abstract

Epilepsy is a common disorder, particularly in poor areas of the world, and can have a devastating effect on people with the disorder and their families. The burden of epilepsy in low-income countries is more than twice that found in high-income countries, probably because the incidence of risk factors is higher. Many of these risk factors can be prevented with inexpensive interventions, but there are only a few studies that have assessed the effect of reducing risk factors on the burden of epilepsy. The mortality associated with epilepsy in low-income countries is substantially higher than in less impoverished countries and most deaths seem to be related to untreated epilepsy (eg, as a result of falls or status epilepticus), but the risk factors for death have not been adequately examined. Epilepsy is associated with substantial stigma in low-income countries, which acts as a barrier to patients accessing biomedical treatment and becoming integrated within society. Seizures can be controlled by inexpensive antiepileptic drugs, but the supply and quality of these drugs can be erratic in poor areas. The treatment gap for epilepsy is high (>60%) in deprived areas, but this could be reduced with low-cost interventions. The substantial burden of epilepsy in poor regions of the world can be reduced by preventing the risk factors, reducing stigma, improving access to biomedical diagnosis and treatment, and ensuring that there is a continuous supply of good quality antiepileptic drugs.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23021288     DOI: 10.1016/S0140-6736(12)61381-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  114 in total

1.  Patient-Reported Adverse Effects Associated with Combination Antiretroviral Therapy and Coadministered Enzyme-Inducing Antiepileptic Drugs.

Authors:  Melissa A Elafros; Gretchen L Birbeck; Joseph C Gardiner; Omar K Siddiqi; Izukanji Sikazwe; Nigel Paneth; Christopher M Bositis; Jason F Okulicz
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

2.  The challenges of managing children with epilepsy in Africa.

Authors:  Jo M Wilmshurst; Angelina Kakooza-Mwesige; Charles R Newton
Journal:  Semin Pediatr Neurol       Date:  2014-01-14       Impact factor: 1.636

3.  'A thing full of stories': Traditional healers' explanations of epilepsy and perspectives on collaboration with biomedical health care in Cape Town.

Authors:  Mpoe Johannah Keikelame; Leslie Swartz
Journal:  Transcult Psychiatry       Date:  2015-02-13

Review 4.  Laboratory Diagnosis of Neurocysticercosis (Taenia solium).

Authors:  Hector H Garcia; Seth E O'Neal; John Noh; Sukwan Handali
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

Review 5.  Cerebral Toxocariasis: Silent Progression to Neurodegenerative Disorders?

Authors:  Chia-Kwung Fan; Celia V Holland; Karen Loxton; Ursula Barghouth
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

6.  International Issues: microfinance in neurologic disorders: a promising role.

Authors:  Janice C Wong; Farrah J Mateen
Journal:  Neurology       Date:  2014-07-22       Impact factor: 9.910

7.  Prevalence of suicide attempts and their risk factors in school-aged patients with epilepsy: a population-based study.

Authors:  Tomor Harnod; Cheng-Li Lin; Chia-Hung Kao
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-02-02       Impact factor: 4.785

8.  Status epilepticus: Using antioxidant agents as alternative therapies.

Authors:  Liliana Carmona-Aparicio; Cecilia Zavala-Tecuapetla; María Eva González-Trujano; Aristides Iii Sampieri; Hortencia Montesinos-Correa; Leticia Granados-Rojas; Esaú Floriano-Sánchez; Elvia Coballase-Urrutía; Noemí Cárdenas-Rodríguez
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

9.  Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.

Authors:  Hector H Garcia; Isidro Gonzales; Andres G Lescano; Javier A Bustos; Mirko Zimic; Diego Escalante; Herbert Saavedra; Martin Gavidia; Lourdes Rodriguez; Enrique Najar; Hugo Umeres; E Javier Pretell
Journal:  Lancet Infect Dis       Date:  2014-07-03       Impact factor: 25.071

Review 10.  Immunology of Taenia solium taeniasis and human cysticercosis.

Authors:  H H Garcia; S Rodriguez; J S Friedland
Journal:  Parasite Immunol       Date:  2014-08       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.